News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Ascentage Pharma (06855.HK) to Present Four Preclinical Advances at AACR 2026 in Poster Sessions
Ascentage Pharma (06855.HK) announced that it will present four preclinical research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeti...
Reset
Send
The window will close in 5 seconds
Ascentage Pharma (06855.HK) to Present Four Preclinical Advances at AACR 2026 in Poster Sessions
Close
Recommend
2
Positive
4
Negative
0
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Ascentage Pharma (06855.HK)  +0.980 (+2.139%)    Short selling $18.02M; Ratio 12.733%   announced that it will present four preclinical research findings in poster sessions at the American Association for Cancer Research (AACR) Annual Meeting 2026, covering three drug candidates, including the novel Class 1 new drug BCR-ABL inhibitor olverembatinib (brand name: Nai Li Ke; development code: HQP1351), the FAK/ALK/ROS1 triple kinase inhibitor APG-2449, and the PRC2/EED inhibitor APG-5918. The meeting will be held from April 17 to 22 in San Diego, California, the United States.

The company stated that the presentations highlight the broader potential of olverembatinib beyond chronic myeloid leukemia (CML), including new applications in endometrial cancer (EC) and mantle cell lymphoma (MCL), as well as combination therapies with BTK inhibitors. In addition, studies of APG-2449 targeting BRAF-mutant tumors and APG-5918 for small cell lung cancer underscore the companys strategic focus on overcoming drug resistance mechanisms and exploring combination treatment strategies. (jl/w)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-24 16:25.)

Related News JPM Cuts Ascentage Pharma (06855.HK) TP to HKD89, Maintains Overweight



This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI
View Original Text

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.